{"id":972,"date":"2018-12-08T02:49:26","date_gmt":"2018-12-08T07:49:26","guid":{"rendered":"http:\/\/www.bocsci.com\/blog\/?p=972"},"modified":"2018-12-08T02:50:34","modified_gmt":"2018-12-08T07:50:34","slug":"latest-clinical-trials-of-lung-and-liver-cancer","status":"publish","type":"post","link":"https:\/\/www.bocsci.com\/blog\/latest-clinical-trials-of-lung-and-liver-cancer\/","title":{"rendered":"Latest Clinical Trials of Lung and Liver Cancer"},"content":{"rendered":"

This article takes stock of the latest clinical development pipeline for lung and liver cancer. We calculated clinical trial data for clinical phase \u2160, and phase \u2161 and phase \u2162 lung cancer drugs registered on clinicaltrials.gov. Included in the statistics are trials that are being recruited, recruited, and issued recruitment notices, and do not include trials that have been completed, terminated, unknown, withdrawn, and suspended.<\/p>\n

Lung Cancer<\/strong><\/p>\n

\"\"<\/a><\/p>\n

As of December 1, 2018, there were 1387 clinical trials of new drugs in the field of lung cancer. Early clinical research was dominant -there were 604 trials in phase \u2160, 595 trials in phase \u2161, and 188 trials in phase 3. Since January 2018, 361 new clinical trials of lung cancer have been added, of which 148 in phase \u2160, 175 in phase \u2161, and 38 in phase \u2162. Clinical trials of new lung cancer drugs have focused on the United States, Asia and Europe. According to the statistics of the research institutes of clinical trials, the top 5 countries or regions are: 797 in the United States, 270 in mainland China, 208 in Spain, 181 in France and 179 in Korea.
\nThe companies that are leading the majority of clinical trials of new lung cancer drugs are: 48 AstraZeneca, 31 Novartis, 26 Bristol-Myers Squibb, 23 Roche, 23 Lilly and 21 Merck.
\nThe average recruitment of lung cancer new drug clinical trials were: 109 in the phase \u2160, 143 in the phase \u2161, and 3 in the third phase.
\nFrom November 1st to 30th, 2018, there were 33 newly released clinical trials of new lung cancer drugs. Among them, there are 12 in phase \u2160, 16 in phase \u2161, and five in phase \u2162.<\/p>\n

 <\/p>\n

\"\"<\/a><\/p>\n

Liver Cancer<\/strong><\/p>\n

\"\"<\/a><\/p>\n

As of December 1, 2018, there were 402 clinical trials of new drugs in the field of liver cancer, and early clinical research was dominant-171 trials in phase \u2160, 159 trials in phase \u2161, and 72 in phase \u2162. Since January 2018, the number of clinical trials of new liver cancer drugs has increased by 104. Among them, there are 47 in phase \u2160, 45 in phase \u2161, and 12 in phase \u2162.<\/p>\n

The clinical trials of new drugs for liver cancer are mainly concentrated in the United States and Asia. According to the statistics of the research institutions in clinical trials, the top 5 countries or regions are: 180 in the United States, 121 in mainland China, 42 in France, 40 in Taiwan, and 36 in South Korea. The companies that are leading the majority of clinical trials for new liver cancer drugs are: Lilly 6, Jiangsu Hengrui 5, Novartis 4, Merck 4 and Teclison Ltd. 3 items. The average recruiting subjects for the new drug trials of liver cancer were: 74 in the phase \u2160, 149 in the phase \u2161, and 333 in the phase \u2162.<\/p>\n

From November 1st to 30th, 2018, there were 11 newly released clinical trials of new liver cancer drugs. Among them, there are 4 in phase \u2160, 5 in phase \u2161, and two in phase \u2162.<\/p>\n

\"\"<\/a><\/p>\n

References<\/p>\n

1. Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., Von Pawel, J., & Cortinovis, D. L. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.\u00a0The Lancet<\/em>,\u00a0389<\/em>(10066), 255-265.<\/p>\n

2. Bull, A., Griffiths, P., & Grundy, S. (2017). 28: Preliminary \u2018virtual review\u2019of lung cancer MDT cases: The impact on diagnostic pathways and MDT meeting efficiency.\u00a0Lung Cancer<\/em>,\u00a0103<\/em>, S13.<\/p>\n

3. Sia, D., Villanueva, A., Friedman, S. L., & Llovet, J. M. (2017). Liver cancer cell of origin, molecular class, and effects on patient prognosis.\u00a0Gastroenterology<\/em>,\u00a0152<\/em>(4), 745-761.<\/p>\n

Related Products<\/strong><\/p>\n

Nivolumab<\/a>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Pembrolizumab<\/a>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cetuximab<\/a><\/p>\n

Chlorogenic acid<\/a>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0Anlotinib<\/a>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Docetaxel<\/a><\/p>\n

Gefitinib<\/a>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0Lenvatinib<\/a>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Atezolizumab<\/a><\/p>\n

Temozolomide<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

This article takes stock of the latest clinical development pipeline for lung and liver cancer. We calculated clinical trial data for clinical phase \u2160, and phase \u2161 and phase \u2162 […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[21,181],"tags":[76,535,128],"_links":{"self":[{"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/posts\/972"}],"collection":[{"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/comments?post=972"}],"version-history":[{"count":3,"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/posts\/972\/revisions"}],"predecessor-version":[{"id":978,"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/posts\/972\/revisions\/978"}],"wp:attachment":[{"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/media?parent=972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/categories?post=972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/tags?post=972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}